Weekly Digest – Jan 2024 Weekly Digest – Jan 2024 22 Jan 2024: Gilead’s Trodelvy fails to extend survival in lung cancer study, prompting selloff Gilead faces a setback as its phase 3 trial for Trodelvy in metastatic non-small cell […]
Weekly Digest – Jan 2024 Weekly Digest – Jan 2024 22 Jan 2024: BioNTech and DualityBio initiate Phase 3 Trial for BNT323/DB-1303 in Metastatic Breast Cancer BioNTech and DualityBio initiate pivotal Phase 3 trial for BNT323/DB-1303, targeting HER2 in metastatic […]
Weekly Digest – Jan 2024 Weekly Digest – Jan 2024 17 Jan 2024: RC48-ADC combos show efficacy in HER2+ and HER2-Low Breast Cancers Disitamab Vedotin (RC48-ADC), a humanized antibody-drug conjugate, demonstrated consistent efficacy and tolerability in a phase 2 study […]
Weekly Digest – Jan 2024 Weekly Digest – Jan 2024 18 Jan 2024: Oxford BioTherapeutics doses first patient with OBT076 in Phase 1b trial for Head and Neck Cancer OBT076 Phase 1b Trial initiation: Oxford BioTherapeutics, in collaboration with GORTEC, […]
